Everolimus Plus Lanreotide vs Everolimus Alone in Aggressive Gastroenteropancreatic Neuroendocrine Tumors

1. JCOG1901 (STARTER-NET) trial evaluated everolimus and lanreotide in aggressive gastroenteropancreatic neuroendocrine tumors. 2. Combination therapy significantly improved median progression-free survival. 3. Adverse events, particularly grade ≥ 3 nonhematologic toxicities, were more common with the combination therapy. 4. Dr. Shagufta Shaheen discussed the potential value of the combination therapy in high-risk patients. 5. The combination therapy was considered promising but not practice-changing by Dr. Shaheen.